Sign in
Taking people in United StatesNo phase

Memory and thinking problems in adults with long-lasting immune thrombocytopenia

Looks for thinking and memory difficulties in adults with immune thrombocytopenia.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
Status
Recruiting
People taking part
100 people, planned
Started
15 Sept 2024
Expected to end
15 Sept 2028
Type of study
Observational
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with persistent or chronic immune thrombocytopenia (ITP, a low platelet count caused by the immune system). Participants take a thinking and memory test and fill in surveys.

Age
18 years or older
Sex
All sexes
Disease stage
Persistent ITP (platelet counts <50 x 109/L on two occasions in the past 3 to 12 months) or chronic ITP (over >12 months).
Earlier treatment
Must have responded to at least 1 earlier ITP treatment, such as corticosteroids, intravenous immune globulin, Rho(D) immune globulin, splenectomy, thrombopoietin receptor agonists or fostamatinib. Other ITP treatments may count if the lead researcher approves.
Biomarker or test result
Platelet counts <50 x 109/L on two occasions.

Main reasons for not taking part

  • Known memory or thinking problems from dementia, stroke or another brain or nerve disease
  • Active mental health problem, such as uncontrolled major depression, schizophrenia, severe anxiety, or alcohol or drug abuse
  • Active cancer that needs or will likely need chemotherapy or surgery, except non-melanoma skin cancer
  • Brain tumor or skull surgery in the past year
  • Serious hearing or vision problems that prevent online testing; people must also be able to follow instructions in English

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults aged ≥ 18 years
  • A clinical diagnosis of persistent or chronic ITP, as defined by a history of platelet counts <50 x 109/L on two occasions in the preceding 3 to 12 months or >12 months, respectively, and documented response to at least 1 prior ITP-directed therapy. ITP-directed therapies include corticosteroids, intravenous immune globulin, Rho(D) immune globulin, splenectomy, thrombopoietin receptor agonists, and fostamatinib. Other qualifying agents used for the treatment of ITP are permissible with approval of the principal investigator
  • Ability to follow instructions in English

Who cannot take part

  • Brain tumor or cranial surgery within the past year
  • Pre-existing diagnosis of cognitive impairment from dementia, stroke, or other neurologic disease
  • Active psychiatric disorder, defined as uncontrolled major depression, schizophrenia, severe anxiety, or active alcohol or drug abuse
  • Active malignancy, requiring or likely to require chemotherapeutic or surgical treatment, except for non-melanoma skin cancer
  • Significant hearing or vision impairment that would preclude the ability to complete neurocognitive testing via a virtual platform

This trial is currently available in United States.

  • Massachusetts General HospitalBoston, United StatesContact: Debbie C Jiang, MDTaking people

About the trial

What the trial wants to find out

Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is:

Read full original descriptionShow less

Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery?

To address this issue, participants will take a cognitive function test and complete surveys on quality of life, fatigue, depression, and cognitive symptoms. The primary aim of the study is to evaluate for the presence and extent of cognitive impairment in patients with ITP. The study will also assess whether cognitive impairment in ITP is associated with patient-reported impacts on quality of life, fatigue, mood, and cognitive symptoms as well as clinical characteristics such as ITP disease and treatment history.

The group in the trial

  • Adults with chronic or persistent ITP

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prevalence, Reproducibility, and Feasibility of Longitudinal Assessment of Neurocognitive Dysfunction in Adults With Chronic and Persistent Immune Thrombocytopenia (COGFIT)
Plain-language title
Memory and thinking problems in adults with long-lasting immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 October 2026